RxDoctor Payments Data

John Bomalaski

Gynecologic Oncology · Lexington, KYNPI 1942273958

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $793 of the $990 with a category attached, or 80.0%. 12 manufacturers reported payments, led by Intuitive Surgical at 41.5% of the total. That places this record below the midpoint for gynecologic oncology clinicians in KY, where the typical reported total is $1,073.

$990in general payments, 2019–2025

Across 28 payments — averaging $35.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$411
  • Merck$125
  • AstraZeneca$93
  • GSK$81
  • Eisai Inc.$71
  • Genmab U.S., Inc.$54
  • plus $157 from 6 others

What the payments were for

  • Food & beverage$79380%
  • Gifts$19820%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$990 in reported general payments places this provider in the 45th percentile of 28 gynecologic oncology providers in Kentucky.

See all gynecologic oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$102,014
Medicare patients
151
Services billed
7,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib25$447,967
LenvimaLenvatinib Mesylate11$271,707
Anastrozole11$385
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$93$447,96725 claims
Eisai Inc.Lenvima$71$271,70711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 28 gynecologic oncology providers in Kentucky.

Other gynecologic oncology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →